Medical News / Coverage ASRS 2019: Chirag Jhaveri, MD: 96-Week Visual and Anatomical Outcomes of Brolucizumab

Heading into the 2019 American Society of Retina Specialists Annual Meeting, sessions and studies pertaining to brolucizumab were an item on the radar of many retina specialists in the constant search for treatments to improve the vision and quality of life for patients. 

 As such, the presentation by Chirag Jhaveri, MD, assistant professor of ophthalmology at the University of Texas Dell Medical School, on the 96-week expanded anatomical and visual outcomes of the HAWK and HARRIER trials was one of the most anticipated sessions of the conference. Source: MDmag By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization

read more

With fixed incomes a reality for many elderly patients, finding less expensive alternatives to current therapies ... read more
Despite not being a physician, Lawrence Hoffheimer, a former healthcare attorney who practice in Washington D.C. ... read more
Results of a new study show that receiving same day intravitreal anti-VEGF treatments was highly preferred ... read more
A study presented at the 2019 American Society of Retina Specialists Annual Meeting is highlighting the ... read more